SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000950127-22-000039
Filing Date
2022-08-12
Accepted
2022-08-12 16:46:10
Documents
1
Group Members
FORESITE CAPITAL FUND V, L.P.FORESITE CAPITAL MANAGEMENT V, LLCFORESITE CAPITAL OPPORTUNITY FUND V, L.P.FORESITE CAPITAL OPPORTUNITY MANAGEMENT V, LLCJAMES TANANBAUM

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D AMENDMENT schedule13damend.htm SC 13D/A 89977
  Complete submission text file 0000950127-22-000039.txt   91789
Mailing Address 300 ONE KENDALL SQUARE, 3RD FLOOR CAMBRIDGE MA 02139
Business Address 300 ONE KENDALL SQUARE, 3RD FLOOR CAMBRIDGE MA 02139 (617) 401-4400
Gemini Therapeutics, Inc. /DE (Subject) CIK: 0001816736 (see all company filings)

IRS No.: 851613057 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-91633 | Film No.: 221160826
SIC: 2834 Pharmaceutical Preparations

Mailing Address 600 MONTGOMERY STREET SUITE 4500 NEW YORK NY 94111
Business Address 600 MONTGOMERY STREET SUITE 4500 NEW YORK NY 94111 415 877 4887
FS Development Holdings, LLC (Filed by) CIK: 0001820810 (see all company filings)

IRS No.: 851613057
Type: SC 13D/A